Two centuries of assessing drug risks

New England Journal of Medicine

Volumn 367, Issue 3, 2012, Pages 193-197

  Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; APROTININ; ARSENIC; CINCHOPHEN; MERCURY; NAPROXEN; PLACEBO; ROFECOXIB; ROSIGLITAZONE; SULFANILAMIDE; THALIDOMIDE;

BLINDNESS; BLISTER; CARDIOVASCULAR RISK; CONVULSION; DEATH; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SHORT SURVEY; SIDE EFFECT; TACHYCARDIA;

EID: 84864005479     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1206652     Document Type: Article

References (5)

1. Holmes OW. Lecture on drugs. In: Bartlett J, ed. Bartlett's familiar quotations. 10th ed. Boston: Little, Brown, 1919.
2. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11. (Pubitemid 46143310)
3. Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J. Under-reporting of cardiovascular events in the rofecoxib Alzheimer's disease studies. Am Heart J 2012. DOI: 10.1016/j.ahj.2012.05.002.
4. Graham DY, Jewell NP, Chan FKL. Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Am J Med Sci 2011;342:356-64.
5. Harris G. F.D.A. says Bayer failed to reveal drug risk study. New York Times. September 30, 2006.